Ginkgo Bioworks and AI drug‑discovery firm Deep Origin lead a multi‑partner consortium that secured up to $31.7 million from ARPA‑H to develop non‑animal models for drug safety and ADME‑Tox prediction. The PREDICTS consortium will build in silico and ex vivo systems to better forecast human toxicity and dosing, aiming to reduce reliance on preclinical animal studies. The project will combine perturbation response profiling, digital pharmacology models, transcriptomics and cell‑painting assays to generate datasets for AI model training and validation. Partners include ImmVue Therapeutics, Mido, Netrias, Sanford Burnham Prebys, and Tessel Biosciences, with Ginkgo providing structured perturbation datasets and Deep Origin contributing digital models. Clarification: ADME‑Tox refers to absorption, distribution, metabolism, excretion and toxicity profiling—key attributes that predict how a drug behaves and its safety in humans.